Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Sponsor: Adagene Inc
Listed as NCT03707093, this PHASE1 trial focuses on Solid Tumors, Non-Hodgkin Lymphoma and remains completed. Sponsored by Adagene Inc, it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Jun 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2018 — Oct 2019 [monthly]
Recruiting PHASE1
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adagene Inc
For direct contact, visit the study record on ClinicalTrials.gov .